Catch-up HPV vaccine effective for women aged up to 20 years, US study suggests
US study confirms effectiveness of quadrivalent human papillomavirus (HPV) vaccine in women aged up to 20 years who receive all three doses, but more research is needed in women aged 21-26 years.
For women aged 14-20 years, catch-up HPV vaccination -- offered if American women miss the recommended vaccination series at 11-12 years -- is effective against the risk of important cervical precancers if women receive all three doses, according to a population case-control study of over 25000 people published in The Lancet Child & Adolescent Health journal.
The study analysed cases of CIN2+ or CIN3+ (cervical intraepithelial neoplasia -- abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer) in a population of women and girls in California (USA).
In the USA, HPV vaccination is recommended for girls aged 11-12. For those who did not receive the vaccine at this age, catch-up vaccination is recommended for girls and women aged 13-26 years. The vaccine is approved as a three-dose series, and the US Centers for Disease Control and Prevention also allows for a two-dose series for girls aged 9-14.
Source: Science Daily